entertainment -WSS

entertainment

author：Wikipedia 2025-09-30 00:35:49 - browse：7443

WASHINGTON — Plenty of pharmaceutical executives have decried Democrats’ new drug pricing law as detrimental to the industry. But few are willing to say they may be willing to delay treatments for cancer patients if it means making more money.

Genentech CEO Alexander Hardy, in an interview with STAT, explained that in the world that existed prior to the Inflation Reduction Act’s passage last year, drugmakers were incentivized to get drugs on the market as fast as possible, regardless of which disease they would be approved to treat.

Now, he’s arguing that the law’s new Medicare negotiation program could encourage Genentech to slow-walk research on how a drug could treat diseases with smaller populations in favor of making sure diseases with larger patient populations are the first to market. That would mean the company would sell more medicines in the window before Medicare is allowed to negotiate prices, because the clock for when discounts can kick in is based off of when the drug first goes on the market.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： A common UTI test for kids haunts adults as a traumatic 'nightmare'

focus

WSS

Will General Catalyst be the first of many hospital takeovers?

FDA proposes changes to key medical devices approval pathway

Hospitals consider fixing cancer drug shortages on their own

What to make of Biden’s latest efforts on cancer research

Telehealth for opioid use disorder is lifesaving

Will General Catalyst be the first of many hospital takeovers?

leisure time

entertainment

Wikipedia

Duchenne breakthrough therapy leaves behind pioneering families

Telehealth for opioid use disorder is lifesaving

After affirmative action ruling, medical educators look to 'holistic review'

Biotech incubator Curie.Bio graduates its first startup

Jerome Adams on the need for new antivirals for Covid

Generate Biomedicines machine learning biotech raises $273M

Jerome Adams on the need for new antivirals for Covid

STAT Executive Editor Rick Berke on STAT's 8th birthday

Alkermes shareholders re

Just how powerful is the placebo effect?

focus

What to make of Biden’s latest efforts on cancer research

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

A common UTI test for kids haunts adults as a traumatic 'nightmare'

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

HPV cancer vaccine study demonstrates efficacy

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

entertainment

focus

Wikipedia

focus